1+ week, 6+ day ago   (140+ words) PharmaDispatch Alterity secures option underwriting as it prepares for pivotal MSA trial Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of…...

2+ week, 4+ day ago   (126+ words) PharmaDispatch Argent BioPharma takes CannEpil into US veterinary regulatory process Chairman Roby Zomer said the development marked the program’s transition from a commercial agreement into formal engagement with the FDA’s veterinary medicines division. … Australian study finds maternal RSV vaccination offers…...

3+ week, 5+ day ago   (136+ words) PharmaDispatch Opportunity #1 - biosimilar policy failure has become impossible to ignore If the promise of biosimilars is only savings for the government, rather than savings and wider access, what is the point from a patient perspective? The one-dimensional focus on savings…...

1+ mon, 4+ day ago   (115+ words) PharmaDispatch Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast AusBiotech has unveiled the integrated program for the 2026 AusBiotech International Conference and AusMedtech Conference, bringing more than 250 speakers together across approximately 60 sessions on the Gold…...

1+ mon, 6+ day ago   (140+ words) PharmaDispatch argenx partners with Monash University and Myostellar to develop muscular therapies Kathryn Evans, General Manager, Australia at argenx, said, “We’re very pleased to further strengthen argenx’s relationship with Monash through the new research collaboration, enabling us to access and…...

1+ mon, 1+ week ago   (119+ words) PharmaDispatch Australian company announces agreement with Lilly to trial lung cancer combination The Australian company had already worked with Lilly to prepare an advanced draft of the clinical study protocol before signing the significant agreement. … The HTA Review and the…...

1+ mon, 4+ week ago   (146+ words) PharmaDispatch Algorae names Nasdaq pharmaceutical chairman to strengthen board Algorae Pharmaceuticals has appointed Troy Valentine as a Non-Executive Director, a move the company says will materially deepen its board capability in capital markets, life sciences governance and international listed-company leadership....

2+ mon, 1+ week ago   (137+ words) PharmaDispatch Ipsen therapy approved in Australia for rare genetic disorder “It is wonderful to have the first treatment approved for this rare disease that significantly impacts children and their families,” said Sally Castle, CEO of the Liver Foundation. … Surely this…...

2+ mon, 2+ week ago   (163+ words) PharmaDispatch A comment that highlights how complexity is making the challenge more challenging You know we have a problem when the minister highlights as an example of the PBS ‘at its best’ a therapy that has never been evaluated for…...

3+ mon, 1+ week ago   (141+ words) Helpful evidence of how the review is landing on outcomes to benefit a few 'Unicorns' PharmaDispatch Helpful evidence of how the review is landing on outcomes to potentially benefit a few 'Unicorns' Is this the outcome people expected, not least…...